Biogen Inc. (NASDAQ: BIIB) reported a 7% increase in earnings for the third quarter of 2019 as spinal muscular atrophy drug Spinraza
Biogen Inc.
-(BIIB)
XNAS:BIIB
Biogen (BIIB) earnings preview: Will stock bounce back after Q3 report?
The market value of pharma giant Biogen, Inc. (NASDAQ: BIIB) declined by a third in March when the stock suffered a heavy
Top biotech stocks to be considered for investment this year
When the massive selloff battered Wall Street in the final months of 2018, biotechnology stocks were no exception. And, most of them
Spinraza helps Biogen beat the street in Q1
A month after announcing the withdrawal from its Phase 3 Alzheimer’s trials, biopharma firm Biogen (NASDAQ: BIIB) on Wednesday reported first-quarter earnings
Biogen ends Alzheimer’s Phase 3 trials, stock plunges above 28%
Shares of the biopharma firms Biogen (NASDAQ: BIIB) and Eisai Co. Ltd (ESALY) plummeted above 28% and 34% respectively at 2 PM
Axsome Therapeutics stock climbs to 34-month high
After the slump on weak quarterly results, investors turned positive on Axsome Therapeutics (AXSM) stock, which climbed to the 34-month high of
ImmunoGen reports Q4 loss; stock gains as results beat estimates
Biotechnology firm ImmunoGen Inc. (IMGN) reported a wider net loss for the fourth quarter, hurt by a sharp fall in revenues. However,
Biogen’s Q4 results beat estimates; revenues up 7%
Biogen Inc. (BIIB) reported revenue and earnings that surpassed market expectations for the fourth quarter of 2018. The stock was up 1.16%
Amgen set to report Q4 earnings on Jan. 29. What’s in store?
Amgen (AMGN) will be reporting its fourth quarter and full-year 2018 earnings results on Tuesday, January 29 after market closes. Analysts expect